CDBIO(SH:688739)2022-11-19 03:26Group 1: Market Overview - The annual issuance of rabies vaccines in the industry is approximately 70 to 80 million doses, indicating a stable demand for human rabies vaccines due to their essential nature [1][2]. - The market for human rabies vaccines is expected to maintain steady growth, driven by increasing disposable income and public awareness regarding rabies prevention [2][3]. Group 2: Impact of COVID-19 - The COVID-19 pandemic has caused a temporary decline in market demand due to restricted activities of people and pets, leading to fewer rabies exposure incidents [1][2]. - Despite the pandemic's impact, the company remains confident in achieving its operational goals and creating greater value in 2022 [2][3]. Group 3: Company Performance and Strategy - The company has established a technical platform for the large-scale cultivation of various viral vaccines, with its human rabies vaccine entering Phase III clinical trials [2][3]. - The company aims to enhance its market position by leveraging its production technology, immunization procedures, and brand value, despite increased competition in the rabies vaccine market [2][4]. Group 4: Future Projections - The company anticipates that the market share of diploid rabies vaccines will increase, although production efficiency and pricing may limit this growth [2][3]. - The company plans to invest 1.4 billion yuan in the commercialization base for the 15-valent HPV vaccine, with a construction period of four years [3][4]. Group 5: Sales and Marketing - The company has increased its sales expenses in 2021 to strengthen its market promotion efforts in response to intensified competition [4][5]. - The sales team operates on a direct sales model, focusing on public health centers, and plans to expand as new products are launched [5][6]. Group 6: Vaccine Development - The company is conducting clinical trials for a new four-dose rabies vaccination schedule, which is recommended by WHO and aims to improve patient convenience [5][6]. - The company is also monitoring opportunities in the animal vaccine market, although it has currently paused its animal rabies vaccine project [5][6].